Outcomes in acute myeloid leukemia among older adults: a five-year retrospective cohort from a Brazilian public hospital
DOI:
https://doi.org/10.46765/2675-374X.2025v6n1e282Keywords:
Leukemia, Myeloid, Acute, Antineoplastic agents, Survival analysisAbstract
Acute myeloid leukemia (AML) remains a significant public health issue in the Brazilian public healthcare system. A retrospective chart review was conducted for patients diagnosed with AML between 2019 and 2024 at a university hospital in northeastern Brazil. Six patients underwent intensive chemotherapy with daunorubicin and cytarabine. Fourteen patients received low-intensity therapy (venetoclax combined with low-dose cytarabine, venetoclax and azacitidine, and azacitidine monotherapy). The overall one-year survival rate in this age group was 28.9%, with a median overall survival of 8.3 months. When stratified by treatment intensity, patients receiving low-intensity therapy had a median overall survival of 10.9 months, compared to 1.1 month for those receiving intensive chemotherapy and 1.5 month for those receiving supportive care alone. The incorporation of low intensity therapies may reduce toxicity and improve survival among elderly patients in low- and middle-income countries.
References
1. Gómez-De León A, Demichelis-Gómez R, da Costa-Neto A, Gómez-Almaguer D, Rego EM. Acute myeloid leukemia: challenges for diagnosis and treatment in Latin America. Hematology. 2023;28(1):2158015. https://doi.org/10.1080/16078454.2022.2158015 DOI: https://doi.org/10.1080/16078454.2022.2158015
2. Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019;36:70–87. https://doi.org/10.1016/j.blre.2019.04.005 DOI: https://doi.org/10.1016/j.blre.2019.04.005
3. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383(7): 617–29. https://doi.org/10.1056/NEJMoa2012971 DOI: https://doi.org/10.1056/NEJMoa2012971
4. Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Champion R, Fiedler W, Pagoni M, Bergeron J, Ting SB, Hou JZ, Anagnostopoulos A, McDonald A, Murthy V, Yamauchi T, Wang J, Jiang Q, Sun Y, Chyla B, Mendes W, DiNardo CD. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy. Blood. 2022;140(25):2754–6. https://doi.org/10.1182/blood.2022016963 DOI: https://doi.org/10.1182/blood.2022016963
5. De la Garza-Salazar F, Colunga-Pedraza PR, Gómez-Almaguer D, García-Zárate VA, Gómez-De León A. Low dose venetoclax plus itraconazole outpatient induction in newly diagnosed acute myeloid leukemia: A phase 2 study. Leuk Res. 2023;133:107373. https://doi.org/10.1016/j.leukres.2023.107373 DOI: https://doi.org/10.1016/j.leukres.2023.107373
6. Zhong X, Wang J, Dai Y, Huang X, Liu J, Xiang B, Ma H. Combining azole antifungals with venetoclax plus azacitidine in patients with newly diagnosed acute myeloid leukemia. Hematology. 2024; 29(1): 2433172. https://doi.org/10.1080/16078454.2024.2433172 DOI: https://doi.org/10.1080/16078454.2024.2433172
7. Willekens C, Bazinet A, Chraibi S, Bataller A, Decroocq J, Arani N, Carpentier B, Rausch C, Lebon D, Maiti A, Gauthier N, Short N, Bonnet S, Sasaki K, Khalife-Hachem S, Swaminathan M, Micol JB, Pasquier F, Marzac C, Roos-Weil D, Pascal L, Daver N, Kadia T, Bouscary D, Ravandi F, Pages A, Kantarjian H, De Botton S, DiNardo C. Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients. Blood Cancer J. 2025; 15(1): 68. https://doi.org/10.1038/s41408-025-01269-x DOI: https://doi.org/10.1038/s41408-025-01269-x
8. Brasil. Ministério da Saúde. Diretrizes diagnósticas e terapêuticas da leucemia mieloide aguda do adulto. Portaria nº 705, de 12 de agosto de 2014. Brasília: Ministério da Saúde; 2014.
9. Silveira DRA, Coelho-Silva JL, Silva WF, Vallance G, Pereira-Martins DA, Madeira MIA, Figueredo-Pontes LL, Velloso EDRP, Simões BP, Peniket A, Danby R, Rego EM, Vyas P, Traina F, Bendit I, Quek L, Rocha V. A multicenter comparative acute myeloid leukemia study: can we explain the differences in the outcomes in resource-constrained settings? Leuk Lymphoma. 2021;62(1):147–57. https://doi.org/10.1080/10428194.2020.1827252 DOI: https://doi.org/10.1080/10428194.2020.1827252
10. Perruso L, Costa Neto A, Silva WF, Nascimento M, Rabelo YS, Mattos ER, Mendes FR, Martins J, Pfister V, Perico MDH, Chiattone C, Rego EM. Disparities in clinical outcomes in patients with newly diagnosed acute myeloid leukemia treated in public versus private services in Brazil: analysis of the Brazilian acute myeloid leukemia registry. Blood. 2024;144(Suppl. 1):5181. https://doi.org/10.1182/blood-2024-212321 DOI: https://doi.org/10.1182/blood-2024-212321
11. Helman R, Santos FP, Simões B, Atta EH, Callera F, Dobbin Jde A, Mattos ÉR, Atalla A, Maiolino A, Zanichelli MA, Diefenbach CF, Delamain MT, Hamerschlak N. Acute myeloid leukemia: update in diagnosis and treatment in Brazil. Einstein. 2011;9(2):179–83. https://doi.org/10.1590/S1679-45082011AO1853 DOI: https://doi.org/10.1590/s1679-45082011ao1853
12. Datoguia TS, Velloso EDRP, Helman R, Musacchio JG, Salvino MA, Soares RA, Higashi M, Fadel AV, E Silva RSA, Hamerschlak N, Santos FPS, Campregher PV. Overall survival of Brazilian acute myeloid leukemia patients according to the European LeukemiaNet prognostic scoring system: a cross-sectional study. Med Oncol. 2018;35(11):141. https://doi.org/10.1007/s12032-018-1179-3 DOI: https://doi.org/10.1007/s12032-018-1179-3
13. Albuquerque KMC, Joventino CB, Moreira LC, Rocha HAL, Gurgel LA, Oliveira DS, Rodrigues CEM. Clinical outcome and prognosis of patients with acute myeloid leukemia submitted to chemotherapy with 5 years of follow-up. Hematol Transfus Cell Ther. 2024;46(1):8–13. https://doi.org/10.1016/j.htct.2022.11.002 DOI: https://doi.org/10.1016/j.htct.2022.11.002
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Hercules Amorim Mota Segundo, Fernando Barroso Duarte
This work is licensed under a Creative Commons Attribution 4.0 International License.
